 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Xenometrix, Inc.
 |
Xenometrix, Inc. |
 |
 |
 |
PROFILE |
 |
Intensive care couldn't fully revive Xenometrix, which Discovery Partners International bought. The biotech firm, which makes testing systems that measure the side effects of certain drugs and the effects of chemicals on cells, had been undergoing financial challenges (the CEO even laid himself off) and had hoped restructuring and an infusion of licensing fees would help it rebound. The firm's Gene Profile Assays measure a gene's response to chemicals and compounds, and its Genotoxicity Assays measure compounds' carcinogenic potential. These products are sold to pharmaceutical, chemical, and biotech customers in the US, Europe, and Japan. The company is a subsidiary of Discovery Partners.
COMPETITION |
 |
Aurora Biosciences Corporation (dossier)
Endogen, Inc. (dossier)
Gene Logic Inc. (GLGC)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 1.90
1-Yr. Sales Growth: (40.2)%
Employees: 4
Revenue per employee: $475,000.00
KEY PEOPLE |
 |
Pauline Gee
CEO
Pauline Gee
CFO
CONTACT INFO |
 |
2425 N. 55th St., Ste. 111
Boulder, CO 80301
US
Phone: 303-447-1773
Fax: 303-447-1758
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |